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Background: The androgen receptor (AR) plays a central role in the oncogenesis of different tumors, as is the case
in prostate cancer. In triple negative breast cancer (TNBC) a gene expression classification has described different
subgroups including a luminal androgen subtype. The AR can be controlled by several mechanisms like the
activation of membrane tyrosine kinases and downstream signaling pathways. However little is known in TNBC
about how the AR is modulated by these mechanisms and the potential therapeutic strategists to inhibit its
expression.
Methods: We used human samples to evaluate the expression of AR by western-blot and phospho-proteomic
kinase arrays that recognize membrane tyrosine kinase receptors and downstream mediators. Western-blots in
human cell lines were carried out to analyze the expression and activation of individual proteins. Drugs against these
kinases in different conditions were used to measure the expression of the androgen receptor. PCR experiments were
performed to assess changes in the AR gene after therapeutic modulation of these pathways.
Results: AR is present in a subset of TNBC and its expression correlates with activated membrane receptor kinases-EGFR
and PDGFRβ in human samples and cell lines. Inhibition of the PI3K/mTOR pathway in TNBC cell lines decreased notably
the expression of the AR. Concomitant administration of the anti-androgen bicalutamide with the EGFR, PDGFRβ and
Erk1/2 inhibitors, decreased the amount of AR compared to each agent given alone, and had an additive anti-proliferative
effect. Administration of dihydrotestosterone augmented the expression of AR that was not modified by the inhibition of
the PI3K/mTOR or Erk1/2 pathways. AR expression was posttranscriptionally regulated by PI3K or Erk1/2 inhibition.
Conclusion: Our results describe the expression of the AR in TNBC as a druggable target and further suggest the
combination of bicalutamide with inhibitors of EGFR, PDGFRβ or Erk1/2 for future development.
Keywords: Tyrosine Kinase Receptor, EGFR/PDFGRβ, PI3K-mTor, Erk1/2, TNBC (triple negative breast cancer),
Kinase Inhibitors, AR (Androgen Receptor)Background
The understanding of the heterogeneity of cancer is of
great importance for the development of effective thera-
peutic strategies in specific subgroups of patients. In-
deed, genomic studies have classified breast cancer into
different subtypes [1]. At a clinical level, this heterogen-
eity corresponds to different prognosis, patterns of re-
lapse, response to treatment and clinical behavior for
each breast cancer subtype. For instance, tumors ex-
pressing estrogen receptors (ER) have a more benevolent
behavior compared with those overexpressing HER2 [2].* Correspondence: albertoo@sescam.jccm.es
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distribution, and reproduction in any mediumIn addition, triple negative breast cancer (TNBC) shows
a worse prognosis compared with tumors expressing
ER, and the probability of early relapse during the first
years after the diagnosed is higher compared with other
subtypes [2,3].
The influence of sex hormones in the development of
breast and prostate cancer is known. Estrogens and an-
drogens act through their receptors by a direct tran-
scriptional regulation of genes involved in cell growth
and survival [4]. In breast cancer, more than 70%–80%
of tumors express the ER or progesterone receptor (PR),
and therapies designed to neutralize their function have
shown clinical benefit [5]. In addition the androgen re-
ceptor (AR) is expressed in breast cancer in 60%–70% ofCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited.
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with a good outcome in ER positive tumors [7]. This good
prognosis is associated with the impeding of the transcrip-
tional activity mediated by the ER [7]. By contrast, in the
apocrine breast cancer subtype- an ER negative tumor-
the AR acts by binding to the same transcription factors
as the ER does, mainly through FOXA1, leading to a lu-
minal gene expression phenotype [8]. In this case the ex-
pression of AR is associated with worse prognosis [8].
Recently, using gene expression analyses TNBC has been
classified in subtypes including one termed luminal andro-
gen that was enriched in genes related to this pathway [9].
Testosterone and particularly dihydrotestosterone (DHT)
are the main activators of the androgen receptor [10]. Upon
ligand binding AR translocate to the nucleus were it acts
transcriptionally [10,11]. Androgens are the major sex hor-
mones in males being produced at different levels but
mainly in sex-related tissues [11]. In addition, in females,
androgens are also formed at the suprarenal gland, having a
functional role after the deprivation of estrogens produced
in the menopause [11].
The control of AR is mediated at different levels, but
signalling pathways play a key role by stabilizing or en-
hancing its transcriptional activity. In prostate cancer,
membrane receptor tyrosine kinases (RTK) have been
shown to modulate the AR expression. For instance,
overexpression of HER2 in cell lines of prostate cancer
results in increase AR activity and stability [12]. Further-
more in breast cancer, a recent study has linked the acti-
vation of HER2 with the expression of AR [13]. Of note,
the PI3K pathway is the key node for the signal trans-
mission of the stimuli from membrane RTKs in relation
to the control of the AR in prostate cancer [14,15]. To
this regard, in breast cancer, mutations at the kinase do-
main of the PI3KCA gene were linked with higher ex-
pression of the AR [16].
In TNBC, expression of the epidermal growth factor re-
ceptor (EGFR) or Platelet-derived Growth Factor Receptor
(PDGFRβ) has been described using immunohistochemical
techniques [17]. A frequent activation of the EGFR and
other receptor (Met and Eph2) as well as non-receptor
(Lyn, Src family kinases) tyrosine kinases has been
confirmed using a profiling of tyrosine phosphorylated
proteins [18]. Moreover using shRNA library screening
several kinases, including the EGFR and HER2, were
identified as activated in TNBC [19].
The mechanism of action of androgens in TNBC re-
mains controversial and the relationship between acti-
vated RTKs and the expression of AR has not been fully
explored, although some recent reports have suggested
the AR as a potential therapeutic target [13].
In order to contribute to a better understanding of the
role of AR in TNBC, the aim of this study is to evaluate
the expression of the AR in TNBC and its relationshipto the activation status of RTKs and its downstream
routes.
Methods
Reagents and antibodies
Cell culture media and supplements (fetal bovine serum
(FBS), glutamine, penicillin/streptomycin) were purchased
from Invitrogen (Gaithersburg, MD). The anti-pErk1/2,
anti-Erk2, anti-PDGFR β, anti-pPDGFR β, anti-EGFR
and anti-pEGFR antibodies were purchased from Santa
Cruz Biotechnology (Santa Cruz, CA). The anti-Akt and
anti-AR antibodies were from Cell Signalling Technologies
(Beverly, MA). The anti-phosphorylated Akt (Serine 473)
antibody was generated against the sequence RPHFPQFpS
473YSAS (p = phosphorylated) [20].
Cell culture
All cell lines were cultured at 37°C in a humidified at-
mosphere in the presence of 5% CO2–95% air. Cells
were grown in DMEM or in RPMI medium containing
a high glucose concentration (4,500 mg/liter) supple-
mented with antibiotics (penicillin at 100 U/ml, strepto-
mycin at 100 μg/ml), glutamine 2 mM and 10% FBS. Cells
were treated with different drugs: PD98059 (50 μM),
BEZ235 (0.5 μM), BIC (20 μM), Imatinib (10 μM), Lapa-
tinib (10 μM) and DHT (50nM).
Identification of human samples and studies
Human samples were obtained from the tumor bank of
the Salamanca University Hospital and Albacete Univer-
sity Hospital following institutional and ethical guide-
lines. All patients signed the study consent form. TNBC
samples were defined as those with HER2 negative by
inmunohistochemistry (IHC), HER2 of 0 or 1+ or a
negative fluorescence in situ hybridization (FISH).
HER2 amplification (evaluated by FISH DAKO HER2
FISH pharmDxTM Kit, DakoCytomation, Glostrup,
Denmark A/S) was defined as a HER2-chromosome 17
ratio of < .2.0, as required by guidelines. Hormone recep-
tor (HR) negative was defined as follow <10% positive cells
by IHC for both estrogen receptor (ER) and progesterone
receptor (PR) following recommendations before 2011.
Protein extraction from human samples
Frozen human samples were inspected by haematoxylin-
eosin staining for epithelial tumor content by analysis of
two slices at each end of the tumor. Only samples con-
taining 70% epithelial tumoral cells were selected for
Western analyses. The tumors were minced, washed with
phosphate-buffered saline (PBS), and homogenized in ice-
cold lysis buffer (140 mM NaCl; 10 mM EDTA; 10% gly-
cerol; 2% Triton X-100; 20 mM Tris pH 7.0; pepstatin,
10 mM; aprotinin, 10 mg/ml; leupeptin, 10 mg/ml; PMSF,
1 mM; beta-glycerophosphate, 25 mM; sodium fluoride,
Cuenca-López et al. BMC Cancer 2014, 14:302 Page 3 of 10
http://www.biomedcentral.com/1471-2407/14/30210 mM; and sodium orthovanadate, 10 mM) with a
tight-fitting Dounce homogenizer. This homogenate was
centrifuged at 10,000 g for 20 minutes at 4 uC, and the
supernatants were transferred to new tubes.
Antibody arrays
Two commercial arrays were used for the studies; the
human phospho-RTK array kit (R&D Systems, Abingdon,
United Kingdom) and the PathScan RTK Signaling
Antibody Array Kit (Cell Signaling). The Image J 1.44
software (National Institute of Health, Bethesda, MD,
USA) was used for the quantification of the different
RTKs in the human phospho-RTK array kit, and the
Odyssey V3.0 program for the quantification of the cell
signalling intermediates.
Western blotting
Cells were washed with phosphate-buffered saline and
lysed in ice-cold lysis buffer (140 mM NaCl, 10 mM
ethylenediaminetetraacetic acid, 10% glycerol, 1%
Nonidet P-40, 20 mM Tris, pH 7.0, 1 μM pepstatin,
1 μg/ml aprotinin, 1 μg/ml leupeptin, 1 mM phenyl-
methyl sulphonyl fluoride (PMSF), and 1 mM sodium
orthovanadate) [21]. Lysates were centrifuged at
10,000 × g at 4°C for 10 min, and supernatants were
transferred to new tubes. Samples were then boiled in
electrophoresis sample buffer and placed on 6%–15%
sodium dodecyl sulfate–polyacrylamide gel electrophor-
esis (SDS-PAGE) gels, depending on the molecular weight
of the proteins to be analyzed. After electrophoresis, pro-
teins in gels were transferred to polyvinylidene difluoride
(PVDF) membranes (Millipore Corporation). Membranes
were blocked in Tris-buffered saline with Tween 20
(TBST) (100 mM Tris [pH 7.5], 150 mM NaCl, 0.05%
Tween 20) containing 1% of bovine serum albumin for
1 hour and then incubated with the corresponding anti-
body for 2–16 hours. After washing with TBST, mem-
branes were incubated with HRP-conjugated anti-mouse
or anti-rabbit secondary antibodies for 30 minutes and
bands were visualized by using ECL Western Blotting De-
tection System (GE Healthcare, Buckinghamshire, United
Kingdom).
Cell proliferation assays
Cells were plated in 24-well plates at 15,000–20,000
cells/well and cultured overnight in DMEM or RPMI +
10% FBS. The next day medium was replaced with
DMEM or RPMI containing the different drugs. Cell
proliferation was analyzed days later by an MTT-based
assay as described [22]. Unless otherwise indicated, the
results are presented as the mean ± standard deviation
(SD) of quadruplicates of a representative experiment
that was repeated at least three times.Revere transcription (RT)-PCR
Total RNA was extracted with RNeasy Mini Kit (Quiagen)
as recommended by the supplier. cDNAs were synthesized
from 5 μg of total RNA by using RevertAid H Minus First
Stand cDNA Synthesis Kit (Fermentas) in a total volume of
20 μl. Reverse transcription was performed at 65° for 5 min
followed by 60 min at 42°. PCR reactions were performed
with 2 μl cDNA in a 50 μl volume and using Taq Polymer-
ase (Biotools) and the following primer pairs (fragments
size indicated in brackets): AR (247 bp) forward 5′-CT
CACCAAGCTCCTGGACTC-3′ and reverse 5′-CAGG-
CAGAAGACATCTGAAAG -3′, β-actin (661 bp), forward
5′-TGACGGGGTCACCCACACTGTGCCCATCTA-3′
and reverse 5′-CTAGAAGCATTTGCGGTGGACGATG-
GAGGG-3′. PCR cycle conditions were 1 min at 95°C,
1 min at 55°C, and 1 min at 72°C for AR and β-actin.
The number of cycles was 35 and the products were re-
solved on a 1% agarose gel and visualized with ethidium
bromide.
The design of this study is approved by the Committee
of Ethics in Research of the University hospital of Albacete
(Reference PI-2010/017).
Results
Expression of AR in human samples and cell lines
We used a panel of eight TNBC cell lines to evaluate the
expression of the AR. Five out of eight cell lines expressed
the AR, except for HBL100, HCC3153, and MDA-MB231.
To corroborate these findings at a genetic level we ex-
tracted gene expression data from public libraries and
evaluated the expression of the AR gene in a panel of cell
lines. BT549 and HS578T (claudin-low subtype) had the
highest level, HCC3153 and HCC70 (basal-like subtype)
the lowest, and MDA-MB231 (claudin-low subtype) and
MDA-MB435 (claudin-low subtype), had low to moderate
levels (Figure 1A).
We next evaluated the expression of the AR in 16 hu-
man samples from triple negative breast cancer patients.
As can be seen in Figure 1B the expression of the AR
was observed in 5 out of 16 tumors (samples number:
2428, 37, 795, 278, 1603). Of note in three of them (sam-
ples number: 2428, 278 and 1603) the expression of the
AR was high.
Expression of the androgen receptor correlates by
activated receptor tyrosine kinases in human samples
Given the fact that one of the mechanisms that control
the expression of the AR in prostate cancer is linked
with kinase signaling pathways, we evaluated if the acti-
vation of membrane RTKs or their downstream path-
ways could be associated with the expression of the AR.
For this purpose, we analyzed the expression of 42 RTKs
and downstream effectors using phospho-specific antibody
arrays in the 16 human samples from TNBC patients. Two
Figure 1 Expression of AR in a panel of TNBC cell lines and in human samples. A) Eight cell lines, Hs578T, MDA-MB231, MDA-MB435, HCC
1187, HBL 100, BT 549, HCC 70 and HCC 3153 were cultured and cell lysates were analyzed by western blot for AR expression. α-tubuline was
used as a loading control. Expression of the AR gene from public gene expression profile data bases. B) Human samples of triple negative breast
cancer patients were processed for protein extraction and lysates were analyzed by western blot for AR expression. α-tubuline was used as a
loading control.
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Additional file 1: Figure S1.
Two RTKs, the PDGFRβ and EGFR, were phosphory-
lated in an important number of patients (more than
20%), and their activation status correlated at a signifi-
cant level with the expression of the AR measured by
western-blot (Figure 2A-B) (Mann–Whitney test: EGFR
and AR: p = 0.03; PDGFRβ and AR: p = 0.004). We did
not identify any association between the activation status
of other RTKs and the expression of the AR (data not
shown). Using a similar approach we studied the kinase
activation profile of proteins involved in the intracellular
signaling mediated by RTKs (Figure 2A, right arm). Of
note pAKT (pAKTS473, pAKTT308) and pErk1/2 were
expressed in more than 40% of the samples. Indeed,
pAKTS473 was expressed in around 90% of the tumors.
Additional file 1: Figure S1 describes the composition of
both arrays and the activation profile of these kinases.
No differences were observed between any of the intra-
cellular signaling proteins- AKT or Erk1/2- and the ex-
pression of the AR (Additional file 2: Figure S2, upper
panel). This lack of association could be explained by
the limited sample size used and the wide expression of
these activated kinases (pAKTS473 is expressed in 90%
of samples and pErk1/2 in more than 40%). However,some samples with a strong activation of pAKTS473 also
showed higher expression of the AR including samples
BT278, BT1603 and BT2428 (Additional file 2: Figure S2,
middle and lower panel).
Activation of tyrosine kinase receptors or downstream
pathways in relation to the expression of the AR in
cell lines
We then studied the expression of RTKs and down-
stream pathways in the panel of TNBC cell lines. EGFR
was activated in HCC1187, BT 549, HCC 70 and HCC
3153; and PDGFR was activated in HS578 and HCC
1187. All these cell lines described, except HCC3153,
expressed the AR (Figure 2C).
In addition we studied downstream activated pathways
including AKT-mTOR and Erk1/2. All cell lines had acti-
vation of pAKT except MDA-MB231. pS6 and pErk1/2
were expressed in all cell lines at different amount levels
(Figure 2C). The high presence of phosphorylated AKT
and Erk1/2 matched the results observed using human
samples, suggesting that these cell lines could be used as a
representative in vitro model. However, the increased ex-
istence of activated AKT and Erk1/2 in most of these cell
lines made difficult to identify any association between the
expression of the AR and the activation of these pathways.
Figure 2 (See legend on next page.)
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Figure 2 Activation of TKRs and their downstream pathways in human samples and in TNBC cell lines. A) Human samples of triple
negative breast cancer patients were processed for protein extraction. Lysates containing 1 mg/ml protein were analyzed for the level of tyrosine
phosphorylation in a panel of 42 receptor tyrosine kinases (RTKs) and citosolic kinases using antibody array kits. The levels of phosphorylated
EGFR, HER2, HER3, PDGFRβ, Akt (S473), Akt (T308) and Erk1/2 are shown (indicated by arrows). B) Relationship between pPDGFRβ and pEGFR and
AR expression in human samples. Activated PDGFRβ and EGFR obtained from the antibody array kit were measured using a gray level scale in
arbitrary units. AR expression measured by western blot was classified in two groups: negative or positive. Statistical difference (p < 0.05) was
analyzed using a Mann–Whitney test. C) Eight cell lines Hs578T, MDA-MB231, MDA-MB435, HCC 1187, HBL 100, BT 549, HCC 70 and HCC 3153
were cultured and cell lysates were analyzed by western blot for the levels of different proteins as well as their phosphorylated forms.
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Given the association observed between some RTKs and
downstream pathways with the expression of the AR in
human samples and cell lines, we evaluated if the pharma-
cological inhibition of these receptors could modify the
expression of the AR.
For this purpose we used two cell lines; BT549, with
constitutive activation of EGFR; and HS578T, with acti-
vation of PDGFRβ. Both cell lines have activation of
AKT, S6 and Erk1/2, being HS578T a cell line with more
activation of Erk1/2. Treatment with imatinib mesylate,
a PDGFβ inhibitor, do not decreased the amount of the
AR in HS578T; and a similar effect was observed for
lapatinib, an EGFR inhibitor, in BT549 (Figure 3A).
As EGFR and PDGFR signal through downstream path-
ways, mainly the PI3k-mTOR and the Erk1/2 pathway, and
these routes have also been implicated in the androgen-
independent control of the AR in prostate cancer, we eva-
luated if the inhibition of these central nodes could have
more effect on the expression of the AR than individual
inhibition of RTKs. Using the same two models, we ob-
served that the administration of PD98059, a MEK inhibi-
tor that inhibits Erk1/2, did not reduce the amount of the
AR (Figure 3A). By contrast the PI3K-mTOR inhibitor
BEZ235 reduced substantially the amount of the AR in
both cell lines (Figure 3A).
We next explored the action of the anti-androgen
bicalutamide when combined with inhibitors of EGFR,
PDGFRβ and the PI3K-mTOR and Erk1/2 pathways.
Interestingly we observed that the concomitant admin-
istration of bicalutamide with EGFR, PDGFRβ and
MEK inhibitors reduced the amount of the AR com-
pared to each agent alone (Figure 3A). This finding was
not observed when combining a PI3K-mTOR inhibitor
with bicalutamide.
Effects on proliferation of tyrosine kinase inhibitors alone
or in combination with bicalutamide
We decided next to evaluate the effect on proliferation of
pharmacological inhibitors of these receptors and path-
ways alone or in combination with antiandrogens. Bicalu-
tamide alone reduced the MTT uptake in both cell lines
(Figure 3B). Interestingly, in both cell lines the combin-
ation of bicalutamide with MEK inhibition was able toproduce a greater anti-proliferative effect than each agent
given alone (p < 0.05). Interestingly, this combination ef-
fect was not observed for BEZ235. In HS578T, imatinib
was unable to reduce the MTT uptake but increased the
anti-proliferative effect of bicalutamide; and in BT549
lapatinib augmented the action of bicalutamide in a simi-
lar manner (Figure 3B). A similar effect was observed
counting cells (Figure 3C).
Action of DHT on the expression of the AR
We then evaluated the action of DHT and bicalutamide on
the expression of AR and how the inhibition of these ki-
nases can modulate its expression. Interestingly administra-
tion of DHT increased the amount of the AR in HS578T
and BT549 (Figure 4A). Administration of bicalutamide did
not reduce the expression of the AR when given alone or in
combination with DHT in BT549. However, in HS578T
bicalutamide partially prevented the amount increase of the
AR in the presence of DHT (Figure 4A). The amount of
the AR gene measured by polymerase chain reaction
(PCR), were not modified by the administration of DHT
suggesting that this is a posttranscriptional mechanism
(Figure 4B). When we evaluated the action of Erk1/2
and PI3K inhibitors on the expression of AR after
stimulation with DHT, we observed that the concomi-
tant administration of BEZ235 was not able to reduce
AR expression as observed previously when given alone
(Figure 3). In the presence of DHT, only bicalutamide is
able to reduce the expression of AR produced by DHT
(Figure 4A). Similarly, BEZ235 or PD98059 given alone;
or BEZ235 and PD98059 in combination with bicaluta-
mide did not modify the amount of the AR gene
(Figure 4B).
Discussion
In the present work, we describe the expression of the
AR in TNBC and its relation to RTKs and their down-
stream signal routes. It is also interesting to remark that
the expression of the AR was studied in cell lines not
representative of a luminal androgen receptor gene ex-
pression subtype [9].
In prostate cancer evidence support the link between
the activation of RTKs, like the insulin-like growth fac-
tor, keratinocyte growth factor, EGFR or HER2, and the
Figure 3 Effect of PI3K/mTOR, Erk1/2 and EGFR/PDGFRβ inhibitors alone or in combination with bicalutamide on the AR expression
and cell proliferation in Hs578T and BT549. A) Effect of drugs on AR expression in Hs578T and BT549. Cells were cultured and treated with
drugs for 24 h. Cell lysates were analyzed by western blot for AR expression. α-tubuline was used as a loading control. B) Effect of drugs on cell
proliferation in Hs578T and BT549. MTT metabolization was performed after 4 days to evaluate cell proliferation. Control cells were untreated.
Statistical difference (* = p < 0.05, Bic versus control or drug combination versus drug alone.) was analyzed using a Test T. C) Effect of drugs on cell
proliferation in Hs578T and BT549. Cell counting was performed after 4 days to evaluate cell proliferation. Control cells were untreated. Statistical
difference (* = p < 0.05, Bic versus control or drug combination versus drug alone.) was analyzed using a Test T.
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[12,23,24]. Particularly signaling through ErbB receptors
and HER2 augment the transcription of the AR; and ac-
tivation of HER2 and HER3 through the HER3-ligand
Neuregulin increases the amount of the AR [12,23].
Therefore inhibition of these kinases sensitizes cells to
androgen withdrawal [23,25]. In estrogen negative breast
cancer, the AR regulates the HER2 function suggestingthat antiandrogens is a potential therapeutic approach
[13]. Indeed, studies in breast cancer using human sam-
ples confirm that those tumors that are HER2 positive ex-
press higher amounts of the AR [26].
In our study we show a correlation between activated
membrane tyrosine kinase receptors and the expression
of the AR in TNBC. It is known that in triple negative
tumors EGFR and PDGFRβ are phosphorylated and
Figure 4 (See legend on next page.)
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Figure 4 Effect of DHT and bicalutamide alone and in combination with PI3K/mTOR, Erk1/2 and EGFR/PDGFRβ inhibitors in AR
expression and cell proliferation. A) Effect of DHT and bicalutamide, BEZ and PD in alone and combined on AR expression in Hs578T and
BT549. Cells were cultured and treated with drugs for 24 h. Cell lysates were analyzed by western blot for AR expression. α-tubuline was used as
loading control. B) In parallel, total RNA was extracted and subjected to RT-PCR. Subsequently, amplification products were resolved on agarose
gel to determine AR mRNA levels. Actin was used as protein loading control and mRNA as gene control.
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trapolating from mechanisms observed in prostate cancer,
is not surprising to identify a correlation between activated
RTKs and the expression of the AR. Interestingly this asso-
ciation was also observed in a panel of cell lines, and treat-
ment with specific tyrosine kinase inhibitors against them
reduced slightly the amount of the AR, particularly with
lapatinib in BT549 when combined with bicalutamide. A
slightly similar effect was observed for imatinib and bica-
lutamide in HS578T. As the PI3K/AKT pathway and the
MAPK pathway are key intracellular signaling nodes from
RTKs, we decided to evaluate their role in the activation of
the AR. It is known that targeting key nodes has a more
profound effect on the inhibition of deregulated functions
that the inhibition of single receptors [28]. In prostate can-
cer the PI3K/AKT pathway has been described as a key
regulator in the transcription of the AR [12], and in breast
cancer mutations at the PIK3CA gene were associated with
expression of the AR in patients [16]. Our results show that
the inhibition of the PI3K/mTOR pathway with BEZ235
decreased the amount of the AR in the absence of
androgens.
It was interesting to find how the concomitant adminis-
tration of an Erk1/2 inhibitor with bicalutamide reduced
the amount of the AR in a more profound manner than
when each agent was given alone. This effect was also ob-
served when using inhibitors of EGFR and PDGFRβ.
We then studied the effect on proliferation of these
combinations. Although an important effect was noted
with BEZ235 given alone, no effect on proliferation was
found when associated with an anti-androgen. Further-
more, the concomitant administration of PD98059 plus
bicalutamide produced a profound arrest in proliferation
compared to each agent given alone. This effect suggests
that the inhibition of the MAPK pathway facilitates the
anti-proliferative effect of anti-androgens. A synergistic
interaction between anti-androgens and Erk1/2 inhibitors
has been described in other models including apocrine
breast cancer, but not in TNBC [29]. A similar result was
observed for the combination of lapatinib and bicaluta-
mide in BT549 and for imatinib in HS578T.
Stimulation with DHT increased the amount of the AR,
and this was not prevented by the administration of either
an inhibitor of PI3K or Erk1/2; showing that the mechan-
ism associated with the expression of the AR by androgens
is independent of a kinase control. Furthermore, effects on
the expression of AR after stimulation with DHT or whenadministering kinase inhibitors were independent of the ex-
pression of the AR gene, suggesting a posttranscriptional
mechanism.
Our findings have some potential therapeutic transla-
tions. It has been suggested that the AR is a potential
druggable target in TNBC and indeed, clinical studies are
currently evaluating the role of androgen deprivation in
the treatment of patients with breast cancer [30]. In our
work we identify a relationship between the expression of
the AR and the activation of membrane kinases like EGFR
and PDGFRβ. Furthermore, the concomitant inhibition
EGFR and PDGFRβ with bicalutamide increased the anti-
proliferative effect compared with each agent given alone.
A similar effect was observed for the administration of the
Erk1/2 inhibitor with bicalutamide.
Conclusions
We observed a positive correlation between the activation
of EGFR and PDGFRβ and the expression of the AR.
Inhibition of PI3K pathway decreased the total amount
of the AR. Inhibition of Erk1/2, PDGFRβ and EGFR
decreased the expression of the AR when given con-
comitantly with bicalutamide and had an additive anti-
proliferative effect, suggesting that administration of
anti-androgens in TNBC should be given concomitantly
with inhibitors of these kinases. Modification of AR expres-
sion by these kinase inhibitors was posttranscriptionally
regulated. In conclusion, our results describe mechanisms
associated with the control of the AR expression in TNBC,
and demonstrate a potential therapeutic opportunity for
the combination of anti-androgens with RTK inhibitors
and its downstream routes.
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Additional file 1: Figure S1. Human Phospho Kinase Array kit
including Receptor Tysosine Kinases and downstream proteins in human
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describe the exact possition of each protein in duplicate. For more details
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Additional file 2: Figure S2. Relationship between pAKTS473,
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described in Figure 1) and classified in two groups: negative or positive.
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where pAKT and pErk1/2 was activated.
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